ePTFE与Dacron移植物在胸主动脉腔内修复术中的早期和长期结果比较
本研究基于前瞻性数据库,比较了ePTFE(Gore TAG)与Dacron(Relay Plus Bolton)两种覆膜支架在胸主动脉腔内修复术(TEVAR)中的早期和晚期结果。共纳入129例降主动脉瘤患者,ePTFE组56例(43.4%),Dacron组73例(56.5%)。两组在早期死亡率、脊髓缺血、内漏及再干预率方面均无显著差异,表明两种移植物在TEVAR中具有相似的疗效。
要点
- ePTFE与Dacron移植物在TEVAR中早期死亡率(8.5%)和脊髓缺血率(2.3%)相似。
- 两组内漏发生率无显著差异,I型16.3%,II型10.9%,III型3.1%。
- 免于再干预率和生存率在两组间无统计学差异。
核心结论
- ePTFE-Gore TAG和Dacron-Relay Plus Bolton在降主动脉瘤TEVAR中表现出相似的早期和晚期结果,包括死亡率、脊髓缺血、内漏和TEVAR相关再干预。
研究设计与样本
- 前瞻性数据库提取2005年2月至2019年2月在三家转诊大学医院接受TEVAR的降主动脉瘤患者,共129例(115男14女),ePTFE组56例(43.4%),Dacron组73例(56.5%)。
主要发现
- 技术成功率100%,急诊手术占22.4%,平均主动脉覆盖长度217.5 ± 91.3,部分去分支37.2%。
- 早期死亡率和脊髓缺血分别为8.5%和2.3%,两组无差异;早期再干预率ePTFE组5.4% vs Dacron组11%(P=0.29)。
- 中位随访32个月(四分位距12-55,范围1-156),I型、II型、III型内漏分别占16.3%、10.9%、3.1%,两组无显著差异。
- 瘤囊缩小率ePTFE组28.6% vs Dacron组39.7%(P=0.19);6、12、24、36个月免于再干预率两组分别为94.0% vs 97.1%、94.0% vs 95.5%、90.8% vs 86.9%、81.1% vs 80.4%(log-rank 0.35,Breslow 0.54)。
- 6、12、24、36个月生存率两组分别为96.0% vs 94.2%、89.3% vs 86.8%、76.5% vs 77.5%、63.3% vs 64.2%(log-rank 0.30,Breslow 0.57)。
关键数值与推荐
- 早期死亡率8.5%,脊髓缺血2.3%,两组无差异。
- I型内漏16.3%,II型10.9%,III型3.1%,两组无显著差异。
- 瘤囊缩小率ePTFE组28.6% vs Dacron组39.7%(P=0.19)。
- 免于再干预率和生存率两组无统计学差异(log-rank P值分别为0.35和0.30)。
临床怎么用
- 在TEVAR中,ePTFE和Dacron移植物均可获得相似的早期和晚期结果,选择可基于术者偏好和患者解剖条件。
- 两种移植物在内漏、再干预和生存方面无显著差异,但需注意本研究样本量有限,结果需更大规模研究验证。
局限性
- 本研究为回顾性分析前瞻性数据库,可能存在选择偏倚。
- 样本量相对较小(129例),可能不足以检测组间微小差异。
- 随访时间中位数32个月,长期结果需进一步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study is to compare early and late results of an expanded polytetrafluoroethylene (ePTFE-Gore TAG®, group A) mesh structured endograft versus a Dacron one (Relay Plus® Bolton, group B) in thoracic endovascular aneurysm repair (TEVAR). METHODS: A prospective database was used to extract information from anonymous patients who underwent TEVAR for descending thoracic aortic aneurysms (DTAAs) between February 2005 and February 2019 at 3 referral university hospitals. Cases treated by means of ePTFE endograft (Gore TAG, group A) and Dacron graft (Relay Plus Bolton, group B) in elective and urgent settings were included. Early and late outcomes were compared. RESULTS: A total of 129 consecutive patients were included (115 men and 14 women). ePTFE-Gore TAG® and Dacron-Relay Plus® Bolton were used in 56 (43.4%) and 73 (56.5%) patients, respectively. Preoperative characteristics of patients were similar. Technical success was 100%. Urgent procedures were 22.4%. Mean aortic coverage and partial debranching were 217.5 ± 91.3 and 37.2%, respectively. Early mortality and spinal cord ischemia (SCI) were 8.5% and 2.3%, respectively, without differences between the 2 groups. Early reintervention was required in 5.4% (group A) and 11% (group B), P = 0.29. Median follow-up was 32 months (interquartile range 12-55 months, range 1-156 months), similar between the 2 groups. Type I endoleak (EL), type II EL, and type III EL were observed in 16.3%, 10.9%, and 3.1% of cases, respectively, without significant differences between the groups. The rate of sac shrinkage was 28.6% in group A vs. 39.7% in group B (P = 0.19). Freedom from reintervention in group A versus group B at 6, 12, 24, and 36 months was 94.0% vs. 97.1%, 94.0% vs. 95.5%, 90.8% vs. 86.9%, and 81.1% vs. 80.4%, respectively (log-rank 0.35, Breslow 0.54). Rate of survival at 6, 12, 24, and 36 months was 96.0% vs. 94.2%, 89.3% vs. 86.8%, 76.5% vs. 77.5%, and 63.3% vs. 64.2%, respectively (log-rank 0.30, Breslow 0.57). CONCLUSIONS: ePTFE-Gore TAG and Dacron-Relay Plus Bolton in DTAA presented similar early and late results in terms of mortality, SCI, EL, and TEVAR-related reinterventions. Effectiveness of TEVAR procedure was confirmed by the high rate of sac shrinkage and it was not influenced by endograft fabric.
引用
- Mezzetto L, Scorsone L, Silingardi R, et al. Early and Long-term Results of ePTFE (Gore TAG®) versus Dacron (Relay Plus® Bolton) Grafts in Thoracic Endovascular Aneurysm Repair. Ann Vasc Surg. 2020. PMID: 32800888. doi:10.1016/j.avsg.2020.07.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。